BPC-157 vs TB-500
Research Verdict
TB-500 is the stronger research reference for the stated comparison criteria. TB-500 won the only direct 2026 head-to-head animal study, but neither peptide has established human healing efficacy and the combination added no benefit.
Quick Answers
Which is better, BPC-157 or TB-500?
TB-500 is the stronger research reference for the stated comparison criteria. TB-500 won the only direct 2026 head-to-head animal study, but neither peptide has established human healing efficacy and the combination added no benefit.
What is the key difference between BPC-157 and TB-500?
BPC-157 has broader preclinical gastrointestinal and multi-tissue claims. TB-500 fragment 17-23 has narrower direct evidence and must be distinguished from full-length thymosin beta-4, which has different chemistry and human trial history.
Evidence Comparison
Direct TB-500 fragment evidence now includes one randomized rat Achilles-tendon study with significant biomechanical and histologic findings. BPC-157 has a much larger rodent literature, concentrated in one research group, but did not significantly improve the total healing score in that independent experiment. RegeneRx human trials tested full-length thymosin beta-4, not TB-500 fragment 17-23.
Evidence Context Favoring BPC-157
GI-specific applications (BPC-157 is stable in gastric acid and has the strongest GI protection data) or multi-tissue healing models where diverse effects are studied.
Evidence Context Favoring TB-500
A direct preclinical Achilles-tendon model where the 2026 fragment-specific rat result is the relevant evidence.
Side-by-Side Snapshot
| Evidence grade | BPC-157: Level B TB-500: Level C |
|---|---|
| Research status | BPC-157: Phase 2 TB-500: Preclinical |
| Primary category | BPC-157: Healing & Recovery TB-500: Healing & Recovery |
| Cited studies | BPC-157: 10 TB-500: 9 |